Join to access to all OVN content. Join for Free
Why Go ALONE? How 2 Aspiring MSLs Reached Their Goal TOGETHER
MSL roles collaboration strategies job search tactics aspiring MSLs mentorship importance

Why Go ALONE? How 2 Aspiring MSLs Reached Their Goal TOGETHER


Share This Article


Summary

In this episode, Tom Caravela is joined by Sierra Birch and George Lehman to discuss the power of collaboration in securing MSL roles. Celebrating a milestone of nearly 250,000 listeners, the episode explores Sierra and George's professional journeys and their organic partnership. They share strategies and beneficial practices for landing MSL positions, while also addressing challenges and ineffective approaches. The conversation highlights the importance of mentors and outlines key requirements for aspiring MSLs. Concluding with a speed round of advice, the episode offers encouragement and appreciation for the audience.

My guests are George Limen, Medical Liaison at Novo Nordisk and Cierra Birch, Molecular Science Liaison with Caris Life Science and discuss how they collaborated to land their first MSL positions
We discuss….

πŸ‘‰ How they joined forces to find success in their job searches
πŸ‘‰ What were some of the most impactful tactics in the process
πŸ‘‰ What challenges they faced along the way
πŸ‘‰ How they dealt with frustration and discouragement
πŸ‘‰ What were the absolute MUSTs for these efforts

Click for Source
MSL roles, collaboration strategies, job search tactics, aspiring MSLs, mentorship importance

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
No β€œD”…No Problem: Finding Success WITHOUT a Doctorate
Partner Avatar MSL Talk: Tom Caravela, Greg Auclair

No β€œD”…No Problem: Finding Success WITHOUT a Doctorate

Podcast
Role of the MSL in launch preparedness for new products and indications
Partner Avatar MSL Talk: Tom Caravela, Matt Goodwin

Role of the MSL in launch preparedness for new products and indications

Article
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
OVN Avatar S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale

Article
Sponsorship of oncology clinical trials in the United States according to age of eligibility
OVN Avatar Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois

Sponsorship of oncology clinical trials in the United States according to age of eligibility

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts KΓ₯gedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Article
Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?
OVN Avatar Karen Geary

Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?

Explore OVN